Although the small sample size of this study did not allow for a definitive conclusion, our findings at least suggest that Th17-dependent inflammation is implicated in the pathogenesis of a subset of RA patients with poor response to TNF-α inhibitors, and that treatment targeting IL-17 may be beneficial for these patients [21,22]. Here, IL17A is linked to rheumatoid arthritis.